Wells Fargo lowered the firm’s price target on uniQure (QURE) to $30 from $35 and keeps an Overweight rating on the shares. The firm notes the regulatory activities of AMT-130 are progressing on track, and it would reiterate its confidence in a successful regulatory outcome for the program. Wells also views AMT-191 data in the second half of 2025 as a new near-term catalyst.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- uniQure reports 2024 EPS ($4.92), consensus ($3.73)
- uniQure’s Promising Pipeline and Strategic Positioning Earns Buy Rating
- uniQure completes enrollment in first cohort of Phase I/IIa trial of AMT-191
- uniQure says IDMC recommends proceeding with dose escalation in AMT-162 trial
- uniQure price target raised to $70 from $25 at H.C. Wainwright